Article published by Beroni Group Limited (NSX: BTG) in the FEBS journal
Sydney, October 28, 2021 AEST (ABN Newswire) – Beroni Group Limited (OTCMKTS: BNIGF) (NSX: BTG), an Australia-based biopharmaceutical company, today announced that its article titled “Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies” has been accepted for publication and made under full review in the FEBS Review.
The FEBS Journal is an international, non-profit, peer-reviewed journal dedicated to publishing high-quality articles reporting significant advances in the molecular life sciences.
The published article relates to scientific findings derived from Beroni’s current research on the development of a medical solution using single domain antibodies (sdAbs) for the SARS-CoV-2 coronavirus. The Company has identified 2 crystal structures of the C-terminal domain of the core protein. The core protein is a major structural protein of SARS-CoV-2 and plays an important role in the packaging, replication, assembly and infection of viral RNA. Through screening a library of sdAbs, the scientific team identified four sdAbs targeting different regions of core protein with high affinities that have future potential for use in viral detection and for therapeutic purposes.
“We are delighted to make further progress in our coronavirus research agenda and to publish our new findings in the journal FEBS. The Company plans to perform a series of experiments to gradually transform the results into clinical trials and find a new avenue for the diagnosis and treatment of the novel coronavirus. Beroni hopes that our efforts can contribute to the basic understanding of the SARS-CoV-2 coronavirus and the global development of antiviral drugs. said Jacky Zhang, Chairman and CEO of the Beroni Group.
The full article can be viewed at:
About Beroni Group Limited
Beroni Group (NSX: BTG) (OTCMKTS: BNIGF) is an international biopharmaceutical company dedicated to the innovation and commercialization of drugs and therapies to fight various global diseases such as cancer and infectious diseases. Its diverse portfolio includes a US FDA-approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceuticals, and a development pipeline targeting oncology and cell therapies. Beroni is present in Australia, the United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Beroni Group Limited